Panacea
Life Sciences, Inc. establishes a presence in Brazil as early as
January 2022
GOLDEN, CO -- December 9, 2021
-- InvestorsHub NewsWire -- Panacea Life Sciences, Inc. (OTCQB:
PLSH), (the "Company"), a cGMP certified, vertically integrated
premium CBD and cannabinoid company, announces new partnership with
MyPharma2Go to enter the growing Brazilian cannabis market. The
partnership reinforces MyPharma2Go's already robust portfolio,
allowing them to ensure a premium service in delivering the best
global cannabis products to customers in Brazil.
Founded in 2017, MyPharma2Go
works with market-leading brands recommended by top professionals
across seven different cross-border e-commerce platforms to provide
patients access to globally available medicines, supplements, and
medical cannabis.
According to André Di Donato,
CEO and founder of MyPharma2Go, in the last five years, MyPharma2Go
has impacted more than 30,000 health professionals and has served
more than 240,000 patients throughout Brazil. He also noted, "With
this partnership with Panacea Life Sciences, we will continue with
our purpose of ensuring a premium service in delivering the best
global products to our customers in Brazil."
Since their founding in 2017,
Panacea Life Sciences has upheld the highest standards for all
their products across multiple categories, from oil drops and
softgels to gummies and topicals. With a focus on Cultivating
Everyday Wellness™
by making products that use
only the highest quality cannabinoids, the brand continues to build
trust and reliability with each new product in its
lineup.
"Panacea is extremely honored
to be accepted into MyPharma2Go's portfolio of quality products for
the people of Brazil" commented Nick Cavarra, Executive Vice
President of Sales & Marketing. "As the largest country in South America
with a population of over 200 million people, our partnership with
MyPharma2Go provides us an incredible pathway to reach Latin
American consumers with Panacea's array of topical and ingestible
products for humans and pets, and in turn, will increase revenues
and shareholder value in 2022."
From the beginning,
MyPharma2Go's goal has always been to make it easier for Brazilians
to buy US-made dietary supplements and OTC products by building an
e-commerce empire for healthcare. They have recently launched a
direct-to-consumer portal that provides detailed information about
the products, support services for their acquisition, and a
personalized customer experience, with the seal of delivery
guarantee throughout the national territory.
About
Panacea Life Sciences Holdings, Inc.
Panacea Life Sciences, Inc. is
a leader in production of legal, trace THC, hemp-derived
cannabinoid products for consumers and pets that operates a 51,000
square foot cGMP certified facility in Golden, Colorado and the
PANA Botanicals farm in western Colorado, complete with fully
integrated extraction, manufacturing, testing and fulfillment.
Panacea produces softgels, gummies, tinctures, sublingual tablets,
cosmetics, and other topicals for purchase online (www.panacealife.com)
and in stores as well as in smart kiosk vending machines being
rolled out nationally.
Panacea, which was founded by
Leslie Buttorff in 2017 as a woman-owned business, has attracted
$20 million in initial investments. In 2019, these were followed up
with a $14 million investment from 22nd
Century Group, Inc. (NASDAQ:
XXII), a leading plant biotechnology company focused on technology
to decrease nicotine in tobacco plants and uses its expertise for
genetic engineering of hemp plants to modify cannabinoid levels
used in manufacturing CBD, CBG and CBN.
If you would like more
information about this topic or to learn more about Panacea and its
products or our land-to-brand practices, please
visit panacealife.com.
Forward-Looking
Statements:
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding our contract in Brazil, including the perceived merits
and anticipated outcome of consumer demand for and suitability of
our products in retail locations and in general, and the expected
growth of the CBD/hemp industry in which we operate. The words
"believe," "may," "estimate," "continue," "anticipate," "intend,"
"should," "plan," "could," "target," "potential," "is likely,"
"will," "expect" and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy, and financial needs. Other risks
are included in filings with the SEC made by Panacea Life Sciences
Holdings, Inc., parent company of Panacea. Any forward-looking
statement made by us herein speaks only as of the date on which it
is made. Factors or events that could cause our actual results to
differ may emerge from time to time, and it is not possible for us
to predict all of them. We undertake no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments, or otherwise, except as may be
required by law.
Contact:
Nick Cavarra
Nick.cavarra@panacealife.com
